Metrics to compare | RVX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRVXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.9x | −5.5x | −0.4x | |
PEG Ratio | −0.07 | 0.07 | 0.00 | |
Price/Book | −0.3x | 0.6x | 2.6x | |
Price / LTM Sales | - | 31.9x | 3.0x | |
Upside (Analyst Target) | - | 152.2% | 51.5% | |
Fair Value Upside | Unlock | −15.4% | 8.8% | Unlock |
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. Its lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein, recent acute coronary syndrome, and post COVID-19 conditions. The company has a partnership with Eversana Life Science Services, LLC to support the commercialization of apabetalone for COVID-19 in the United States and Canada; developing cardiovascular and pulmonary arterial hypertension indications; and Medison Pharma Ltd. The company is headquartered in Calgary, Canada.